Farmakogenomik Hepatotoksisitas Obat Anti Tuberkulosis

Andri Dwi Wahyudi, Soedarsono Soedarsono

= http://dx.doi.org/10.20473/jr.v1-I.3.2015.103-108
Abstract views = 87 times | views = 122 times

Abstract


Anti-TB drugs (ATD) associated with hepatotoxicity is a serious medical problem in the world, especially for patients with TB. The production and expenditures toxic drug metabolites depends on the activity of some enzymes, such as N-acetyl transferase 2 (NAT2), Cytochrome P450 oxidase (CYP2E1) and Glutathione S-transferase (GSTM1). Variations from the DNA sequence or polymorphism at this locus (NAT2, CYP2E1 and GSTM1) can modulate enzyme activity and can affect the risk of hepatotoxicity. Hepatotoxicity is generally unpredictable and occur in a small number of patients even when the drug was given according to the recommended dosage. Among the ATD, the metabolism of INH, which is one of the ATD forefront, has been studied extensively, and said acetylation by NAT2, oxidation by cytochrome P450 oxidase (CYP2E1) and detoxified by GST play an important role in the INH-induced hepatotoxicity. Since the prevalence of polymorphisms is different in worldwide populations, the risk of ATD hepatotoxicity varies in the populations. Thus, the knowledge of polymorphisms at these loci, prior to medication, may be useful in evaluating risk and controlling ATD hepatotoxicity.


Keywords


Pharmacogenomics, Hepatotoxicity, ATD, Tuberculosis

Full Text:

PDF

References


Farrell GC: Drug-induced acute hepatitis. In: Drug-induced liver disease Farrell GG (Ed.). Churchill Livingstone, Edinburgh, UK.1994; 247-299.

Pessayre D, Larrey D: Drug-induced liver injury: In: Oxford Textbook of clinical Hepatology. Volume 2. (Eds). Oxford University Press, Oxford, UK. 1991.

Sim E, Payton M, Noble M, Minchin R: An update on genetic, structural and functional studies on arylamine N-acetyltransferases in eucaryotes and procaryotes. Hum. Mol. Genet.2000; 9: 2435-2441.

Nebert DW: Polymorphism in drug-metabolizing enzymes: what is their clinical relevance and why do they exist. Am. J. Hum. Genet. 1997; 60: 265-271.

Yamamoto T, Suou T, Hirayama C: Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986: 6; 295-298.

Benichou C: Criteria of drug induced liver disorder: report of an International Consensus Meeting. J. Hepatol. 1990: 11; 272-276.

Larrey D. Epidemiology and individual susceptibility to adverse drug reactions aff ecting the liver. Semin Liver Dis. 2002; 22; 145-55.

Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006; 354: 731-9.

Rapp RS, Campbell RW, Howell JC, Kendig ELJ: Isoniazid hepatotoxicity in children. Am. Rev. Respir. Dis. 1978: 118; 794- 796.

Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK: Risk Factors for hepatotoxicity from antituberculous drugs: a case control study. Thorax 1996: 51; 132-136.

Girling DJ: The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle. 1978: 59; 13-32.

Fountain FF, Tolley E, Chrisman CR, Self TH: Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005: 128; 116-123.

Saukkonen JJ, Cohn DL, Jasmer RM et al.: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 2006: 174; 935-952.

Garg PK, Tandon RK: Antituberculous Agents Induced Liver Injury. In: Drug-induced Liver Disease. Kaplowitz N, Deleve LD (Eds). Marcel Dekker, New York, USA. 2003.

Sarma GR, Immanuel, C, Kailasam S, Narayana AS, Venkatesan P: Rifampicininduced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampicin. Am. Rev. Respir. Dis. 1986: 133; 1072-1075.

Upton AM, Mushtaq A, Victor TC et al.: Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol. Microbiol. 2001: 42; 309-317.

Description of different alleles at NAT2 and corresponding acetylating status www.louisville.edu/medschool/pharmacology/nat.html

Golka K, Blaszkewicz M, Samimi M, Bolt HM, Selinski S: Reconstruction of N-acetyltransferase 2 haplotypes using PHASE. Arch. Toxicol. (2007) (Epub ahead of print).

A software to restructure the haplotypes from genotype data www. stat.washington.edu/stephens/

Cho HJ, Koh WJ, Ryu YJ et al.: Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb.) 2007: 87; (6), 551-556.

Huang YS, Chern HD, Su WJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis druginduced hepatitis. Hepatology. 2003: 37; 924-930.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Jurnal Respirasi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

View My Satats

Indexed by: